Amyloid-β Peptides Interact with Plasma Proteins and Erythrocytes: Implications for Their Quantitation in Plasma

Kuo, Yu-Min; Kokjohn, Tyler A.; Kalback, Walter; Luehrs, Dean; Galasko, Douglas R.; Chevallier, Nathalie; Koo, Edward H.; Emmerling, Mark R.; Roher, Alex E.

doi:10.1006/bbrc.2000.2222

Cited by 230Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchProtein Interaction Studies and Fluorescence Analysis

Amyloid-β Peptides Interact with Plasma Proteins and Erythrocytes: Implications for Their Quantitation in Plasma

Kuo, Yu-Min, Kokjohn, Tyler A., Kalback, Walter, Luehrs, Dean, Galasko, Douglas R., Chevallier, Nathalie, Koo, Edward H., Emmerling, Mark R. +1 more·2000·Biochemical and Biophysical Research Communications

DOI 10.1006/bbrc.2000.2222

Open this paper in CoChat — free account

Abstract

Amyloid beta peptides are bound rapidly in the plasma complicating an accurate assessment of their in vivo abundance by immunoassay procedures. The extent of Abeta immunoassay interference was used to estimate the Abeta binding capacity of purified plasma proteins, erythrocytes and whole plasma. Human serum albumin bound Abeta peptides rapidly with a 1:1 stoichiometry and at physiological concentrations was capable of binding over 95% of an input of 5 ng/ml Abeta. Purified alpha2-macroglobulin was able to bind Abeta peptides and at physiological concentration bound 73% of 5 ng/ml of Abeta. Erythrocytes also sequestered the Abeta peptides, showing a preference for binding Abeta 1-42. Incubation of 5 ng/ml of Abeta in plasma revealed that about 30% of the peptides were still detectable by immunoassay, presumably reflecting the binding of Abeta peptides with albumin and other plasma molecules. Thus, our studies reveal that both the soluble and formed elements of the blood are capable of sequestering Abeta peptides. To avoid underestimating plasma Abeta values, we employed an improved column chromatography method under denaturing conditions to liberate Abeta from its associations with plasma proteins. Quantification of Abeta 40 and 42 levels in plasma from both normal and AD individuals after chromatography showed a large overlap between AD and control groups, despite the very large pool of Abeta present in the AD brains. The potential origins of the plasma Abeta pool are discuss…

Integrity signals

Registry

Crossref · 10.1006/bbrc.2000.2222

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Aβ-C3b-CR1-mediated interactions sequester Aβ42 to promote clearance to the periphery.
“CR1 is predominantly expressed by erythrocytes (343, 344) and A 𝛃 -C3b-CR1-mediated interactions sequester A 𝛃 42 to promote clearance to periphery (180, 338), suggesting that CR1 variants can increase free blood A 𝛃 levels (343), which in turn can promote RAGE-mediated A 𝛃 re-entry across the BBB into the brain.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [338]

Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.
Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268 · see citing works
Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210 · see citing works
Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599 · see citing works
Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731 · see citing works
Reduction of β‐amyloid peptide<sub>42</sub> in the cerebrospinal fluid of patients with Alzheimer's disease
Motter, R., Vigo‐Pelfrey, C., Kholodenko, D., Barbour, R., Johnson‐Wood, K., Galasko, D., Chang, L., Miller, B., Clark, C., Green, R., et al. (1995) · Annals of Neurology · doi:10.1002/ana.410380413 · Cited by 701 · see citing works
Self-citation
Cerebrospinal Fluid β-Amyloid(1-42) in Alzheimer Disease: Differences Between Early- and Late-Onset Alzheimer Disease and Stability During the Course of Disease
Andreasen, N., Hesse, C., Davidsson, P., Minthon, L., Wallin, A., Winblad, B., Vanderstichele, H., Vanmechelen, E., & Blennow, K. (1999) · Archives of Neurology · doi:10.1001/archneur.56.6.673 · Cited by 660 · see citing works
Alpha-2 macroglobulin is genetically associated with Alzheimer disease
Blacker, D., Wilcox, M., Laird, N. M., Rodes, L., Horvath, S. M., Go, R. C. P., Perry, R. T., Watson, B., Bassett, S. S., McInnis, M. G., et al. (1998) · Nature Genetics · doi:10.1038/1243 · Cited by 642 · see citing works
LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted β-amyloid precursor protein and mediates its degradation
Kounnas, M. Z., Moir, R. D., Rebeck, G. W., Bush, A. I., Argraves, W. S., Tanzi, R. E., Hyman, B. T., & Strickland, D. K. (1995) · Cell · doi:10.1016/0092-8674(95)90320-8 · Cited by 489 · see citing works
Interleukin‐6 and α‐2‐macroglobulin indicate an acute‐phase state in Alzheimer's disease cortices
Bauer, J., Strauss, S., Schreiter-Gasser, U., Ganter, U., Schlegel, P., Witt, I., Yolk, B., & Berger, M. (1991) · FEBS Letters · doi:10.1016/0014-5793(91)80737-n · Cited by 483 · see citing works
Analysis of Heterogeneous βA4 Peptides in Human Cerebrospinal Fluid and Blood by a Newly Developed Sensitive Western Blot Assay
Ida, N., Hartmann, T., Pantel, J., Schrüder, J., Zerfaß, R., Fürstl, H., Sandbrink, R., Masters, C. L., & Beyreuther, K. T. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.37.22908 · Cited by 476 · see citing works
Amyloid β-protein deposition in tissues other than brain in Alzheimer's disease
Joachim, C. L., Mori, H., & Selkoe, D. J. (1989) · Nature · doi:10.1038/341226a0 · Cited by 462 · see citing works
Expression of β amyloid protein precursor mRNAs: Recognition of a novel alternatively spliced form and quantitation in alzheimer's disease using PCR
Golde, T. E., Estus, S., Usiak, M., Younkin, L. H., & Younkin, S. G. (1990) · Neuron · doi:10.1016/0896-6273(90)90100-t · Cited by 431 · see citing works
Transthyretin sequesters amyloid beta protein and prevents amyloid formation.
Schwarzman, A. L., Gregori, L. L., Vitek, M. P., Lyubski, S., Strittmatter, W. J., Enghilde, J. J., Bhasin, R., Silverman, J. M., Weisgraber, K. H., & Coyle, P. K. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.18.8368 · Cited by 410 · see citing works
Pathological alterations of the cerebral microvasculature in Alzheimer's disease and related dementing disorders
Buée, L., Hof, P. R., Bouras, C., Delacourte, A., Perl, D. P., Morrison, J. H., & Fillit, H. M. (1994) · Acta Neuropathologica · doi:10.1007/bf00294173 · Cited by 331 · see citing works
Amyloid β-Peptide Is Transported on Lipoproteins and Albumin in Human Plasma
Biere, A. L., Ostaszewski, B., Stimson, E. R., Hyman, B. T., Maggio, J. E., & Selkoe, D. J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.51.32916 · Cited by 331 · see citing works
Platelets Are the Primary Source of Amyloid β-Peptide in Human Blood
Chen, M., Inestrosa, N. C., Ross, G. S., & Fernandez, H. L. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2103 · Cited by 320 · see citing works
Localization of Alzheimer βA4 amyloid precursor protein at central and peripheral synaptic sites
SCHUBERT, W. J., Prior, R., Weidemann, A., Dircksen, H., Multhaup, G., Masters, C. L., & Beyreuther, K. T. (1991) · Brain Research · doi:10.1016/0006-8993(91)91532-6 · Cited by 265 · see citing works
Fate of Cerebrospinal Fluid‐Borne Amyloid β‐Peptide: Rapid Clearance into Blood and Appreciable Accumulation by Cerebral Arteries
Ghersi‐Egea, J. ‐., Gorevic, P. D., Ghiso, J., Frangione, B., Patlak, C. S., & Fenstermacher, J. D. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.67020880.x · Cited by 222 · see citing works
α 2 -macroglobulin associates with β-amyloid peptide and prevents fibril formation
Hughes, S. R., Khorkova, O., Goyal, S., Knäblein, J., Heroux, J. A., Riedel, N. G., & Sahasrabudhe, S. R. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.3275 · Cited by 212 · see citing works
Characterization of Apolipoprotein J-Alzheimer's Aβ Interaction
Matsubara, E., Frangione, B., & Ghiso, J. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.13.7563 · Cited by 195 · see citing works
High Levels of Circulating Aβ42 Are Sequestered by Plasma Proteins in Alzheimer's Disease
Kuo, Y., Emmerling, M. R., Lampert, H. C., Hempelman, S. R., Kokjohn, T. A., Woods, A. S., Cotter, R. J., & Roher, A. E. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0552 · Cited by 182 · see citing works
Self-citation
Endogenous Proteins Controlling Amyloid β-Peptide Polymerization
Bohrmann, B., Tjernberg, L. O., Kuner, P., Poli, S. M., Levet‐Trafit, B., Näslund, J., Richards, G. J., Huber, W., Döbeli, H., & Nordstedt, C. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.23.15990 · Cited by 157 · see citing works
Secretion of Alzheimer's disease Abeta amyloid peptide by activated human platelets.
Li, Q., Whyte, S., Tanner, J. E., Evin, G. M., Beyreuther, K. T., & Masters, C. L. (1998) · PubMed · Cited by 155 · see citing works
Fusogenic Properties of the C-terminal Domain of the Alzheimer β-Amyloid Peptide
Pillot, T., Goethals, M., Vanloo, B., Talussot, C., Brasseur, R., Vandekerckhove, J. S., Rosseneu, M., & Lins, L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.46.28757 · Cited by 152 · see citing works
Cerebrovascular Accumulation and Increased Blood‐Brain Barrier Permeability to Circulating Alzheimer's Amyloid β Peptide in Aged Squirrel Monkey with Cerebral Amyloid Angiopathy
Mackic, J. B., Weiss, M., Miao, W., Kirkman, E., Ghiso, J., Calero, M., Bading, J., Frangione, B., & Zlokovic, B. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.70010210.x · Cited by 140 · see citing works
Alpha 1-antichymotrypsin regulates Alzheimer beta-amyloid peptide fibril formation.
Eriksson, S., Janciauskiene, S. M., & Lannfelt, L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.6.2313 · Cited by 137 · see citing works
alpha2-Macroglobulin as a beta-amyloid peptide-binding plasma protein.
Du, Y., Ni, B., Glinn, M. A., Dodel, R. C., Bales, K. R., Zhang, Z., Hyslop, P. A., & Paul, S. M. (1997) · PubMed · Cited by 132 · see citing works
Aβ25–35 induces rapid lysis of red blood cells: contrast with Aβ1–42 and examination of underlying mechanisms
Mattson, M. P., Begley, J. G., Mark, R. J., & Furukawa, K. (1997) · Brain Research · doi:10.1016/s0006-8993(97)00824-x · Cited by 124 · see citing works
α2‐Macroglobulin Attenuates β‐Amyloid Peptide 1–40 Fibril Formation and Associated Neurotoxicity of Cultured Fetal Rat Cortical Neurons
Du, Y., Bales, K. R., Dodel, R. C., Liu, X. F., Glinn, M. A., Horn, J. W., Little, S. P., & Paul, S. M. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.70031182.x · Cited by 114 · see citing works
α2‐Macroglobulin as a β‐Amyloid Peptide‐Binding Plasma Protein
Du, Y., Ni, B., Glinn, M. A., Dodel, R. C., Bales, K. R., Zhang, Z., Hyslop, P. A., & Paul, S. M. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69010299.x · Cited by 114 · see citing works
Increased plasma amyloid β protein 1–42 levels in Down syndrome
Mehta, P. D., Dalton, A. J., Mehta, S. P., Kim, K. S., Sersen, E. A., & Wisniewski, H. M. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(97)00966-x · Cited by 108 · see citing works
Degradation of Amyloid β-Protein by a Serine Protease-α2-Macroglobulin Complex
Qiu, W. Q., Borth, W., Ye, Z., Haass, C., Teplow, D. B., & Selkoe, D. J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.14.8443 · Cited by 98 · see citing works
Molecular Cloning of the cDNA and Chromosome Localization of the Gene for Human Ubiquitin-conjugating Enzyme 9
Wang, Z., Qiu, Q., Seufert, W., Taguchi, T., Testa, J. R., Whitmore, S. A., Callen, D. F., Welsh, D., Shenk, T. E., & Deuel, T. F. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.40.24811 · Cited by 91 · see citing works
Alzheimer's soluble amyloid β is a normal component of human urine
Ghiso, J. A., Calero, M., Matsubara, E., Governale, S., Chuba, J. V., Beavis, R. C., Wısnıewskı, T., & Frangione, B. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00400-6 · Cited by 90 · see citing works
Genetic association of alpha2-macroglobulin with Alzheimer's disease in a Finnish elderly population.
Myllykangas, L., Polvikoski, T. M., Sulkava, R. O., Verkkoniemi, A., Crook, R., Tienari, P. J., Pusa, A., Niinistö, L., O’Brien, P. C., KONTULA, K. K., et al. (1999) · PubMed · Cited by 79 · see citing works
High levels of circulating beta-amyloid peptide do not cause cerebral beta-amyloidosis in transgenic mice.
Fukuchi, K., Ho, L., Younkin, S. G., Kunkel, D. D., Ogburn, C. E., LeBoeuf, R. C., Furlong, C. E., Deeb, S. S., Nochlin, D., Węgiel, J., et al. (1996) · Europe PMC (PubMed Central) · Cited by 69 · see citing works
Alzheimer's Peptide Aβ1–42 Binds to Two β-Sheets of α1-Antichymotrypsin and Transforms It from Inhibitor to Substrate
Janciauskiene, S. M., Rubin, H. N., Lukacs, C., & Wright, H. T. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.43.28360 · Cited by 64 · see citing works
Alzheimer amyloid β‐peptides exhibit ionophore‐like properties in human erythrocytes
Engström, I., Ronquist, G. K., Pettersson, L., & Waldenström, A. P. (1995) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1995.tb01732.x · Cited by 63 · see citing works
Amyloid P component and other acute-phase proteins associated with cerebellar Aβ-deposits in Alzheimer's disease
Kalaria, R. N., & Perry, G. L. (1993) · Brain Research · doi:10.1016/0006-8993(93)91202-4 · Cited by 46 · see citing works
Complement interactions with amyloid β1–42: A nidus for inflammation in AD brains
Watson, M. D., Roher, A. E., Kim, K. S., Spiegel, K., & Emmerlin, M. R. (1997) · Amyloid · doi:10.3109/13506129709014379 · Cited by 39 · see citing works
Self-citation
Human neutrophil phagocytic granules contain a truncated soluble form of the Alzheimer beta/A4 amyloid precursor protein (APP)
Nordstedt, C., Näslund, J., Thyberg, J., Messamore, E., Gandy, S., & Terenius, L. Y. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)36954-5 · Cited by 18 · see citing works
The β-amyloid epitope masking activity in human brain is identified as albumin
Matsumoto, A., Minami, M., & Matsumoto, R. (1997) · Neuroreport · doi:10.1097/00001756-199710200-00021 · Cited by 7 · see citing works
Untitled work
Kordower (1999) · doi:10.1002/1531-8249(199909)46:3
Untitled work
(1999) · doi:10.1002/1531-8249(199904)45:4
Untitled work
Webster (1996) · doi:10.1002/(sici)1097-4547(19961001)46:1

Flagged first, then by citations

1 of the 46 references couldn’t be matched to a known paper.

Sorted by citations

Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease
Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326 · see citing works
Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease
the European Alzheimer's Disease Initiative Investigators, Lambert, J.-C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., Combarros, O., Zelenika, D., Bullido, M. J., et al. (2009) · Nature Genetics · doi:10.1038/ng.439 · Cited by 2,234 · see citing works
Blood-Brain Barrier: From Physiology to Disease and Back
Sweeney, M. D., Zhao, Z., Montagne, A., Nelson, A. R., & Zlokovic, B. V. (2019) · Physiological Reviews · doi:10.1152/physrev.00050.2017 · Cited by 2,294 · see citing works
A systemic view of Alzheimer disease — insights from amyloid-β metabolism beyond the brain
Wang, J., Gu, B. J., Masters, C. L., & Wang, Y.-J. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.111 · Cited by 808 · see citing works
Amyloid β Protein and Alzheimer’s Disease: When Computer Simulations Complement Experimental Studies
Nasica-Labouze, J., Nguyen, P. H., Sterpone, F., Berthoumieu, O., Buchete, N., Côté, S., Simone, A. D., Doig, A. J., Faller, P., Garcı́a, A. E., et al. (2015) · Chemical Reviews · doi:10.1021/cr500638n · Cited by 583 · see citing works
<scp>A</scp>rizona <scp>S</scp>tudy of <scp>A</scp>ging and <scp>N</scp>eurodegenerative <scp>D</scp>isorders and <scp>B</scp>rain and <scp>B</scp>ody <scp>D</scp>onation <scp>P</scp>rogram
Beach, T. G., Adler, C. H., Sue, L. I., Serrano, G., Shill, H. A., Walker, D. G., Lue, L., Roher, A. E., Dugger, B. N., Maarouf, C., et al. (2015) · Neuropathology · doi:10.1111/neup.12189 · Cited by 460 · see citing works
Self-citation
In-depth analysis of the membrane and cytosolic proteome of red blood cells
Pasini, E. M., Kirkegaard, M., Mortensen, P., Lutz, H. U., Thomas, A. W., & Mann, M. (2006) · Blood · doi:10.1182/blood-2005-11-007799 · Cited by 425 · see citing works
Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease
Roher, A. E., Esh, C. L., Kokjohn, T. A., Castaño, E. M., Vickle, G. D. V., Kalback, W. M., Patton, R., Luehrs, D. C., Daugs, I. D., Kuo, Y., et al. (2008) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2008.10.004 · Cited by 411 · see citing works
Self-citation
Standardization of measurement of β-amyloid<sub>(1-42)</sub>in cerebrospinal fluid and plasma
Vanderstichele, H., Kerschaver, E. V., Hesse, C., Davidsson, P., Buyse, M.-A., Andreasen, N., Minthon, L., Wallin, A., Blennow, K., & Vanmechelen, E. (2000) · Amyloid · doi:10.3109/13506120009146438 · Cited by 301 · see citing works
Age but Not Diagnosis Is the Main Predictor of Plasma Amyloid β-Protein Levels
Fukumoto, H., Tennis, M. K., Locascio, J. J., Hyman, B. T., Growdon, J. H., & Irizarry, M. C. (2003) · Archives of Neurology · doi:10.1001/archneur.60.7.958 · Cited by 258 · see citing works
The Sun Health Research Institute Brain Donation Program: Description and Eexperience, 1987–2007
Beach, T., Sue, L., Walker, D., Roher, A., Lue, L., Vedders, L. J., Connor, D., Sabbagh, M., & Rogers, J. (2007) · Cell and Tissue Banking · doi:10.1007/s10561-008-9067-2 · Cited by 265 · see citing works
Self-citation
Clearance mechanisms of Alzheimer's amyloid-β peptide: implications for therapeutic design and diagnostic tests
Bates, K. A., Verdile, G., Li, Q.-X., Ames, D., Hudson, P., Masters, C. L., & Martins, R. N. (2009) · Molecular Psychiatry · doi:10.1038/mp.2008.96 · Cited by 247 · see citing works
CSF Biomarkers for Alzheimer's Disease Diagnosis
Arunagiri, A., Singh, P. K., Jacob, R. S., & Maji, S. K. (2010) · International Journal of Alzheimer s Disease · doi:10.4061/2010/606802 · Cited by 197 · see citing works
Peripheral clearance of amyloid β peptide by complement C3-dependent adherence to erythrocytes
Rogers, J., Li, R., Mastroeni, D., Grover, A., Leonard, B., Ahern, G., Cao, P., Kolody, H., Vedders, L., Kolb, W. P., et al. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.09.043 · Cited by 175 · see citing works
Quantitative analysis of amyloid β peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry
Oe, T., Ackermann, B. L., Inoue, K., Berna, M. J., Garner, C. O., Gelfanova, V., Dean, R. A., Siemers, E., Holtzman, D. M., Farlow, M. R., et al. (2006) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.2787 · Cited by 166 · see citing works
Serum Albumin Prevents Protein Aggregation and Amyloid Formation and Retains Chaperone-like Activity in the Presence of Physiological Ligands
Finn, T., Nunez, A. C., Sunde, M., & Easterbrook‐Smith, S. B. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.372961 · Cited by 162 · see citing works
Human Serum Albumin Can Regulate Amyloid-β Peptide Fiber Growth in the Brain Interstitium
Stanyon, H. F., & Viles, J. H. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.c112.360800 · Cited by 164 · see citing works
An Update on Blood-Based Markers of Alzheimer’s Disease Using the SiMoA Platform
Li, D., & Mielke, M. M. (2019) · Neurology and Therapy · doi:10.1007/s40120-019-00164-5 · Cited by 147 · see citing works
Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer’s disease
Wang, M. J., Yi, S., Han, J.-Y., Park, Y. H., Jang, J., Chun, I. K., Kim, S. E., Lee, B. S., Kim, G. J., Yu, J. S., et al. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0324-0 · Cited by 152 · see citing works
Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker
Toledo, J. B., Shaw, L. M. J., & Trojanowski, J. Q. (2013) · Alzheimer s Research & Therapy · doi:10.1186/alzrt162 · Cited by 135 · see citing works
Studies of Aβ Pharmacodynamics in the Brain, Cerebrospinal Fluid, and Plasma in Young (Plaque-Free) Tg2576 Mice Using the γ-Secretase Inhibitor N2-[(2 S)-2-(3,5-Difluorophenyl)-2-hydroxyethanoyl]-N1-[(7 S)-5-methyl-6-oxo-6,7-dihydro-5 H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY-411575)
Lanz, T. A., Hosley, J. D., Adams, W. J., & Merchant, K. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.060715 · Cited by 130 · see citing works
Cystatin C in Alzheimer's disease
Kaur, G., & Levy, E. (2012) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2012.00079 · Cited by 132 · see citing works
Genetic markers for diagnosis and pathogenesis of Alzheimer's disease
Kim, D., Yeo, S. H., Park, J.-M., Choi, J. Y., Lee, T.-H., Park, S. Y., Ock, M. S., Eo, J., Kim, H., & Cha, H. (2014) · Gene · doi:10.1016/j.gene.2014.05.031 · Cited by 128 · see citing works
Cystatin C in aging and in Alzheimer’s disease
Mathews, P. M., & Levy, E. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.06.003 · Cited by 133 · see citing works
APP/Aβ structural diversity and Alzheimer's disease pathogenesis
Roher, A. E., Kokjohn, T. A., Clarke, S. G., Sierks, M. R., Maarouf, C. L., Serrano, G. E., Sabbagh, M., & Beach, T. G. (2017) · Neurochemistry International · doi:10.1016/j.neuint.2017.08.007 · Cited by 121 · see citing works
Self-citation
Insights into the mechanisms of action of anti‐Aβ antibodies in Alzheimer's disease mouse models
Levites, Y., Smithson, L. A., Price, R. W., Dakin, R. S., Yuan, B., Sierks, M. R., Kim, J., McGowan, E., Kim Reed, D., Rosenberry, T. L., et al. (2006) · The FASEB Journal · doi:10.1096/fj.06-6463fje · Cited by 113 · see citing works
β-Amyloid Directly Inhibits Human α4β2-Nicotinic Acetylcholine Receptors Heterologously Expressed in Human SH-EP1 Cells
Wu, J., Kuo, Y., George, A. A., Xu, L., Hu, J., & Lukas, R. J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m400335200 · Cited by 112 · see citing works
Self-citation
Human Serum Albumin Inhibits Aβ Fibrillization through a “Monomer-Competitor” Mechanism
Milojevic, J., Raditsis, A., & Melacini, G. (2009) · Biophysical Journal · doi:10.1016/j.bpj.2009.08.028 · Cited by 104 · see citing works
Plasma levels of amyloid β-protein 42 are increased in women with mild cognitive impairment
Assini, A., Cammarata, S., Vitali, A., Colucci, M. E. W., Giliberto, L., Borghi, R., Inglese, M. L., Volpe, S., Ratto, S., Dagna-Bricarelli, F., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000137040.64252.ed · Cited by 104 · see citing works
Efficacy and Safety of Plasma Exchange with 5% Albumin to Modify Cerebrospinal Fluid and Plasma Amyloid-β Concentrations and Cognition Outcomes in Alzheimer’s Disease Patients: A Multicenter, Randomized, Controlled Clinical Trial
Boada, M., Anaya, F., Ortiz, P., Olazarán, J., Shua-Haim, J. R., Obisesan, T. O., Hernández, I., Muñoz, J., Buendia, M., Alegret, M., et al. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160565 · Cited by 94 · see citing works
Plasma A 42 and A 40 as markers of cognitive change in follow-up: a prospective, longitudinal, population-based cohort study
Seppälä, T. T., Herukka, S., Hänninen, T., Tervo, S., Hallikainen, M., Soininen, H. S., & Pirttilä, T. (2010) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2010.205757 · Cited by 95 · see citing works
Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer's disease
Aluise, C. D., Robinson, R. A. S., & Butterfield, D. A. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.07.008 · Cited by 92 · see citing works
Amyloid 1-42 peptide alters the gating of human and mouse -bungarotoxin-sensitive nicotinic receptors
Grassi, F., Palma, E., Tonini, R., Amici, M., Ballivet, M., & Eusebi, F. (2003) · The Journal of Physiology · doi:10.1113/jphysiol.2002.035436 · Cited by 93 · see citing works
Disease-Modifying Therapies in Alzheimer???s Disease
ll, M. H., Berger, T., & Heneka, M. T. (2006) · Drugs · doi:10.2165/00003495-200666160-00004 · Cited by 94 · see citing works
Autoantibodies to Redox-modified Oligomeric Aβ Are Attenuated in the Plasma of Alzheimer's Disease Patients
Moir, R. D., Tseitlin, K. A., Soscia, S. J., Hyman, B. T., Irizarry, M. C., & Tanzi, R. E. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414176200 · Cited by 88 · see citing works
Amyloid β Levels in Human Red Blood Cells
Kiko, T., Nakagawa, K., Satoh, A., Tsuduki, T., Furukawa, K., Arai, H., & Miyazawa, T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049620 · Cited by 88 · see citing works
Serum albumin and beta-amyloid deposition in the human brain
Kim, J. W., Byun, M. S., Lee, J. H., Yi, D., Jeon, S. Y., Sohn, B. K., Lee, J.-Y., Shin, S. A., Kim, Y. K., Kang, K. M., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000010005 · Cited by 87 · see citing works
Neural stem cell therapy for neurovascular injury in Alzheimer's disease
Boese, A. C., Hamblin, M. H., & Lee, J. (2019) · Experimental Neurology · doi:10.1016/j.expneurol.2019.113112 · Cited by 88 · see citing works
CR1 in Alzheimer's Disease
Zhu, X., Yu, J., Jiang, T., Wang, P., Cao, L., & Tan, L. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8723-8 · Cited by 84 · see citing works
β-Amyloid (Aβ) protein in cerebrospinal fluid as a biomarker for Alzheimer’s disease
Andreasen, N., & Blennow, K. (2002) · Peptides · doi:10.1016/s0196-9781(02)00056-6 · Cited by 83 · see citing works
Abnormal amyloid beta metabolism in systemic abnormalities and Alzheimer’s pathology: Insights and therapeutic approaches from periphery
Ullah, R., Park, T. J., Huang, X., & Kim, M. O. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101451 · Cited by 78 · see citing works
Molecular Insights into Human Serum Albumin as a Receptor of Amyloid-β in the Extracellular Region
Choi, T. S., Lee, H. J., Han, J. Y., Lim, M. H., & Kim, H. I. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b08584 · Cited by 76 · see citing works
Red cell perturbations by amyloid β-protein
Rajadas, J., Kusiak, J. W., Chrest, F. J., Demehin, A. A., Jayaraman, M., Wersto, R. P., Nagababu, E., Ravi, L. B., & Rifkind, J. M. (2003) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(03)00101-6 · Cited by 74 · see citing works
The binding constant for amyloid Aβ40 peptide interaction with human serum albumin
Rózga, M., Kłoniecki, M., Jabłonowska, A., Dadlez, M., & Bal, W. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.10.080 · Cited by 73 · see citing works
A Nanoplasmonic Biosensor for Ultrasensitive Detection of Alzheimer’s Disease Biomarker Using a Chaotropic Agent
Kim, H., Lee, J. U., Kim, S., Song, S., & Sim, S. J. (2019) · ACS Sensors · doi:10.1021/acssensors.8b01242 · Cited by 73 · see citing works
Dynamic changes of oligomeric amyloid β levels in plasma induced by spiked synthetic Aβ42
An, S. S. A., Lee, B. S., Yu, J. S., Lim, K., Kim, G. J., Lee, R., Kim, S., Kang, S., Park, Y. H., Yang, Y. S., et al. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0310-6 · Cited by 73 · see citing works
Apolipoprotein C-III is an Amyloid-β-Binding Protein and an Early Marker for Alzheimer's Disease
Shih, Y., Tsai, K., Lee, C.-W., Shiesh, S., Chen, W.-T., Pai, M., & Kuo, Y. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-140111 · Cited by 71 · see citing works
Self-citation
Metallothionein-III Antagonizes the Neurotoxic and Neurotrophic Effects of Amyloid β Peptides
Irie, Y., & Keung, W. M. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.4594 · Cited by 69 · see citing works
Amyloid β-interacting partners in Alzheimer's disease: From accomplices to possible therapeutic targets
Han, S.-H., Park, J.-C., & Mook-Jung, I. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.12.004 · Cited by 67 · see citing works
Autoimmune Responses to Amyloid Structures of Aβ(25–35) Peptide and Human Lysozyme in the Serum of Patients with Progressive Alzheimer’s Disease
Алексеевна, Г. М., Davudova, T. B., Mališauskas, M., Zamotin, V., Sewell, R. D. E., Voskresenskaya, N. I., Kostanyan, I. A., Sherstnev, V. V., & Morozova‐Roche, L. A. (2004) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000079197 · Cited by 65 · see citing works
Consideration of Sex Differences in the Measurement and Interpretation of Alzheimer Disease-Related Biofluid-Based Biomarkers
Mielke, M. M. (2019) · The Journal of Applied Laboratory Medicine · doi:10.1373/jalm.2019.030023 · Cited by 65 · see citing works
Chemically treated plasma Aβ is a potential blood-based biomarker for screening cerebral amyloid deposition
Park, J.-C., Han, S.-H., Cho, H. J., Byun, M. S., Yi, D., Choe, Y. M., Kang, S., Jung, E. S., Won, S. J., Kim, E. H., et al. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0248-8 · Cited by 63 · see citing works
Understanding Effects of PAMAM Dendrimer Size and Surface Chemistry on Serum Protein Binding with Discrete Molecular Dynamics Simulations
Wang, B., Sun, Y., Davis, T. P., Ke, P. C., Wu, Y., & Ding, F. (2018) · ACS Sustainable Chemistry & Engineering · doi:10.1021/acssuschemeng.8b01959 · Cited by 62 · see citing works
Rapid Detection of Aβ Aggregation and Inhibition by Dual Functions of Gold Nanoplasmic Particles: Catalytic Activator and Optical Reporter
Choi, I., & Lee, L. P. (2013) · ACS Nano · doi:10.1021/nn402310c · Cited by 63 · see citing works
Charge Dependent Retardation of Amyloid β Aggregation by Hydrophilic Proteins
Assarsson, A., Hellstrand, E., Cabaleiro-Lago, C., & Linse, S. S. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn400124r · Cited by 62 · see citing works
Blood Amyloid-β Oligomerization as a Biomarker of Alzheimer’s Disease: A Blinded Validation Study
Youn, Y. C., Lee, B. S., Kim, G. J., Ryu, J. S., Lim, K., Lee, R., Suh, J., Park, Y. H., Pyun, J., Ryu, N., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200061 · Cited by 63 · see citing works
Chemical characterization of pro-inflammatory amyloid-beta peptides in human atherosclerotic lesions and platelets
Kokjohn, T. A., Vickle, G. D. V., Maarouf, C. L., Kalback, W. M., Hunter, J. M., Daugs, I. D., Luehrs, D. C., Lopez, J. C., Brune, D. C., Sue, L. I., et al. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.07.004 · Cited by 60 · see citing works
Self-citation
The immune system, amyloid‐β peptide, and Alzheimer's disease
Weksler, M. E., Gouras, G. K., Relkin, N. R., & Szabo, P. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00264.x · Cited by 59 · see citing works
Antibody‐based approaches in Alzheimer’s research: safety, pharmacokinetics, metabolism, and analytical tools
Lichtlen, P., & Mohajeri, M. H. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05064.x · Cited by 59 · see citing works
Crosstalk between zinc and free fatty acids in plasma
Coverdale, J. P. C., Khazaipoul, S., Arya, S., Stewart, A. J., & Blindauer, C. A. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2018.09.007 · Cited by 59 · see citing works
Amyloid-β oligomerization monitored by single-molecule stepwise photobleaching
Dresser, L. G., Hunter, P., Yendybayeva, F., Payne-Dwyer, A. L., Howard, J. A. L., Evans, G. J., Leake, M. C., & Quinn, S. D. (2020) · Methods · doi:10.1016/j.ymeth.2020.06.007 · Cited by 55 · see citing works
Interactions of β-amyloid peptide with fibrinogen and coagulation factor XII may contribute to Alzheimer's disease
Ahn, H. J., Chen, Z.-L., Zamolodchikov, D., Norris, E. H., & Strickland, S. (2017) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000368 · Cited by 54 · see citing works
Peripheral complement interactions with amyloid β peptide: Erythrocyte clearance mechanisms
Brubaker, W. D., Crane, A., Johansson, J. U., Yen, K., Garfinkel, K., Mastroeni, D., Asok, P., Bradt, B. M., Sabbagh, M. N., Wallace, T. L., et al. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.03.010 · Cited by 53 · see citing works
The Cu(II)/Aβ/Human Serum Albumin Model of Control Mechanism for Copper-Related Amyloid Neurotoxicity
Rózga, M., & Bal, W. (2009) · Chemical Research in Toxicology · doi:10.1021/tx900358j · Cited by 51 · see citing works
Complement receptor 1 polymorphisms and risk of late-onset Alzheimer's disease.
Zhang, Q., Yu, J.-T., Zhu, Q.-X., Zhang, W., Wu, Z.-C., Miao, D., & Tan, L. (2010) · Brain Research · doi:10.1016/j.brainres.2010.06.018 · Cited by 53 · see citing works
Amyloid β-induced erythrocytic damage and its attenuation by carotenoids
Nakagawa, K., Kiko, T., Miyazawa, T., Sookwong, P., Tsuduki, T., Satoh, A., & Miyazawa, T. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.03.060 · Cited by 51 · see citing works
Multifunctional Effect of Human Serum Albumin Reduces Alzheimer’s Disease Related Pathologies in the 3xTg Mouse Model
Ezra, A., Rabinovich-Nikitin, I., Rabinovich‐Toidman, P., & Solomon, B. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150694 · Cited by 50 · see citing works
Advances in Amyloid-β Clearance in the Brain and Periphery: Implications for Neurodegenerative Diseases
Ullah, R., & Lee, E. J. (2023) · Experimental Neurobiology · doi:10.5607/en23014 · Cited by 49 · see citing works
Human serum albumin in neurodegeneration
Shojai, S., Rohani, S., Moosavi‐Movahedi, A. A., & Habibi-Rezaei, M. (2022) · Reviews in the Neurosciences · doi:10.1515/revneuro-2021-0165 · Cited by 47 · see citing works
Dissecting the Interactions between Human Serum Albumin and α-Synuclein: New Insights on the Factors Influencing α-Synuclein Aggregation in Biological Fluids
Bellomo, G., Bologna, S., Cerofolini, L., Paciotti, S., Gatticchi, L., Ravera, E., Parnetti, L., Fragai, M., & Luchinat, C. (2019) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.9b02381 · Cited by 47 · see citing works
Depression and Plasma Amyloid β Peptides in the Elderly With and Without the Apolipoprotein E4 Allele
Sun, X., Chiu, C. C., Liebson, E. S., Crivello, N. A., Wang, L., Claunch, J. D., Folstein, M. F., Rosenberg, I. H., Mwamburi, D. M., Peter, I., et al. (2009) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31819cb3ac · Cited by 46 · see citing works
Metabolic Abnormalities of Erythrocytes as a Risk Factor for Alzheimer's Disease
Kosenko, E. A., Tikhonova, L. A., Montoliu, C., Barreto, G. E., Aliev, G., & Kaminsky, Y. G. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00728 · Cited by 46 · see citing works
Protein kinase C as a peripheral biomarker for Alzheimer’s disease
de Barry, J., Mbebi, C., & Janoshazi, A. K. (2009) · Experimental Gerontology · doi:10.1016/j.exger.2009.10.015 · Cited by 45 · see citing works
In Vitro Amyloid-β Binding and Inhibition of Amyloid-β Self-Association by Therapeutic Albumin
Milojevic, J., Costa, M., Ortiz, A. M., Jorquera, J. I., & Melacini, G. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-131169 · Cited by 43 · see citing works
β -Amyloid Peptide Vaccination Results in Marked Changes in Serum and Brain A β Levels in APPswe/PS1ΔE9 Mice, as Detected by SELDI-TOF-Based ProteinChip ® Technology
Vehmas, A. K., Borchelt, D., Price, D. L., McCarthy, D. B., Wills-Karp, M. A., Peper, M. J., Rudow, G. L., Luyinbazi, J., Siew, L. T., & Troncoso, J. C. (2001) · DNA and Cell Biology · doi:10.1089/10445490152717578 · Cited by 43 · see citing works
Tratamiento de la enfermedad de Alzheimer mediante terapia combinada de aféresis terapéutica y hemoféresis con albúmina e inmunoglobulina intravenosa: fundamentos y aproximación terapéutica al estudio AMBAR (Alzheimer Management By Albumin Replacement)
Boada, M., Ramos‐Fernández, E., Guivernau, B., Muñoz, F. J., Costa, M., Ortiz, A. M., Jorquera, J. I., Núñez, L., Torres, M., & Páez, A. (2014) · Neurología · doi:10.1016/j.nrl.2014.02.003 · Cited by 41 · see citing works
The clinical significance of plasma clusterin and Aβ in the longitudinal follow-up of patients with Alzheimer’s disease
Hsu, J., Lee, W., Liao, Y., Wang, S., & Fuh, J. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0319-x · Cited by 41 · see citing works
The peripheral blood of Aβ binding RBC as a biomarker for diagnosis of Alzheimer's disease
Lan, J., Liu, J., Zhao, Z., Xue, R., Zhang, N., Zhang, P., Zhao, P., Zheng, F., & Sun, X. (2015) · Age and Ageing · doi:10.1093/ageing/afv009 · Cited by 40 · see citing works
Insight into the Inhibition Effect of Acidulated Serum Albumin on Amyloid β-Protein Fibrillogenesis and Cytotoxicity
Xie, B., Li, X., Dong, X., & Sun, Y. P. (2014) · Langmuir · doi:10.1021/la5025197 · Cited by 40 · see citing works
A truncated and dimeric format of an Affibody library on bacteria enables FACS‐mediated isolation of amyloid‐beta aggregation inhibitors with subnanomolar affinity
Lindberg, H., Härd, T., Löfblom, J., & Ståhl, S. (2015) · Biotechnology Journal · doi:10.1002/biot.201500131 · Cited by 39 · see citing works
Variability in Blood-Based Amyloid-β Assays: The Need for Consensus on Pre-Analytical Processing
Watt, A. D., Perez, K. A., Rembach, A., Masters, C. L., Villemagne, V. L., & Barnham, K. J. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120058 · Cited by 38 · see citing works
Clearance and transport of amyloid β by peripheral monocytes correlate with Alzheimer’s disease progression
Huang, X., Fowler, C. J., Li, Y., Li, Q.-X., Sun, J., Pan, Y., Jin, L., Perez, K. A., Dubois, C., Lim, Y. Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52396-1 · Cited by 37 · see citing works
Human Albumin Impairs Amyloid β-peptide Fibrillation Through its C-terminus: From docking Modeling to Protection Against Neurotoxicity in Alzheimer's disease
Picón-Pagès, P., Bonet, J., Garcı́a-Garcı́a, J., Garcia-Buendia, J., Gutiérrez, D. A., Valle, J., Gómez-Casuso, C. E. S., Sidelkivska, V., Alvarez, A. R., Perálvarez‐Marín, A., et al. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.06.017 · Cited by 38 · see citing works
Soluble aggregates of the amyloid-β peptide are trapped by serum albumin to enhance amyloid-β activation of endothelial cells
Barcelo, A. A. R., Gonzalez-Velasquez, F. J., & Moss, M. A. (2009) · Journal of Biological Engineering · doi:10.1186/1754-1611-3-5 · Cited by 9 · see citing works
Serum Albumin's Protective Inhibition of Amyloid-β Fiber Formation Is Suppressed by Cholesterol, Fatty Acids and Warfarin
Bode, D. C., Stanyon, H. F., Hirani, T., Baker, M. D., Nield, J., & Viles, J. H. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.01.008 · Cited by 37 · see citing works
Morphological changes induced in erythrocyte by amyloid beta peptide and glucose depletion: A combined atomic force microscopy and biochemical study
Carelli‐Alinovi, C., Dinarelli, S., Sampaolese, B., Misiti, F., & Girasole, M. (2018) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2018.07.009 · Cited by 36 · see citing works
Maximizing the Potential of Plasma Amyloid-Beta as a Diagnostic Biomarker for Alzheimer’s Disease
Oh, E. S., Troncoso, J. C., & Tucker, S. M. F. (2008) · NeuroMolecular Medicine · doi:10.1007/s12017-008-8035-0 · Cited by 35 · see citing works
CLU, CR1 and PICALM genes associate with Alzheimer's-related senile plaques
Kok, E., Luoto, T. M., Haikonen, S., Goebeler, S., Haapasalo, H. K., & Karhunen, P. J. (2011) · Alzheimer s Research & Therapy · doi:10.1186/alzrt71 · Cited by 35 · see citing works
Treatment of Alzheimer disease using combination therapy with plasma exchange and haemapheresis with albumin and intravenous immunoglobulin: Rationale and treatment approach of the AMBAR (Alzheimer Management By Albumin Replacement) study
Boada, M., Ramos‐Fernández, E., Guivernau, B., Muñoz, F. J., Costa, M., Ortiz, A. M., Jorquera, J. I., Núñez, L., Torres, M., & Páez, A. (2016) · Neurología (English Edition) · doi:10.1016/j.nrleng.2014.02.009 · Cited by 34 · see citing works
Peripheral complement interactions with amyloid β peptide in Alzheimer's disease: 2. Relationship to amyloid β immunotherapy
Crane, A., Brubaker, W. D., Johansson, J. U., Trigunaite, A., Ceballos, J., Bradt, B. M., Glavis‐Bloom, C., Wallace, T. L., Tenner, A. J., & Rogers, J. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.04.015 · Cited by 34 · see citing works
Albumin Alters the Conformational Ensemble of Amyloid-β by Promiscuous Interactions: Implications for Amyloid Inhibition
Xie, H., & Guo, C. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.629520 · Cited by 34 · see citing works
Bapineuzumab Alters Aβ Composition: Implications for the Amyloid Cascade Hypothesis and Anti-Amyloid Immunotherapy
Roher, A. E., Cribbs, D. H., Kim, R. C., Maarouf, C. L., Whiteside, C. M., Kokjohn, T. A., Daugs, I. D., Head, E., Liebsack, C., Serrano, G. E., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059735 · Cited by 34 · see citing works
Self-citation
Detection and quantification of plasma amyloid-β by selected reaction monitoring mass spectrometry
Kim, J. S., Ahn, H., Cho, S. M., Lee, J. E., Kim, Y. S., & Lee, C. (2014) · Analytica Chimica Acta · doi:10.1016/j.aca.2014.06.024 · Cited by 36 · see citing works
Methionine 35 oxidation reduces toxic effects of the amyloid β-protein fragment (31–35) on human red blood cell
Clementi, M. E., Martorana, G. E., Pezzotti, M., Giardina, B., & Misiti, F. (2004) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2004.03.006 · Cited by 33 · see citing works
Changes in Phospholipid Composition of Erythrocyte Membrane in Alzheimer’s Disease
Oma, S., Mawatari, S., Saito, K., Wakana, C., Tsuboi, Y., Yamada, T., & Fujino, T. (2012) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000341603 · Cited by 32 · see citing works
Emerging insights into the role of albumin with plasma exchange in Alzheimer’s disease management
Costa, M., & Páez, A. (2021) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2021.103164 · Cited by 32 · see citing works
Over‐expression of amyloid precursor protein in HEK cells alters p53 conformational state and protects against doxorubicin
Uberti, D. L., Cenini, G., Olivari, L., Ferrari‐Toninelli, G., Porrello, E., Cecchi, C., Pensafini, A., Liguri, G., Govoni, S. M., Racchi, M., et al. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04757.x · Cited by 31 · see citing works
Based on molecular structures: Amyloid-β generation, clearance, toxicity and therapeutic strategies
Yang, H., Li, J., Li, X., Ma, L., Hou, M., Zhou, H., & Zhou, R. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.927530 · Cited by 30 · see citing works
HSA targets multiple Aβ42 species and inhibits the seeding-mediated aggregation and cytotoxicity of Aβ42 aggregates
Wang, C., Cheng, F., Xu, L., & Jia, L. (2016) · RSC Advances · doi:10.1039/c6ra14590f · Cited by 30 · see citing works
Albumin Exchange in Alzheimer's Disease: Might CSF Be an Alternative Route to Plasma?
Menéndez‐González, M., & Gasparovic, C. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01036 · Cited by 28 · see citing works

Distribution of Aβ peptide in whole blood
Slemmon, J. R., Painter, C. L., Nadanaciva, S., Catana, F., Cook, A., Motter, R. N., & Seubert, P. A. (2006) · Journal of Chromatography B · doi:10.1016/j.jchromb.2006.08.003 · Cited by 14 · see citing works
High Levels of Circulating Aβ42 Are Sequestered by Plasma Proteins in Alzheimer's Disease
Kuo, Y., Emmerling, M. R., Lampert, H. C., Hempelman, S. R., Kokjohn, T. A., Woods, A. S., Cotter, R. J., & Roher, A. E. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0552 · Cited by 182 · see citing works
Self-citation
Amyloid β-Peptide Is Transported on Lipoproteins and Albumin in Human Plasma
Biere, A. L., Ostaszewski, B., Stimson, E. R., Hyman, B. T., Maggio, J. E., & Selkoe, D. J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.51.32916 · Cited by 331 · see citing works
P3–098: Proteomic analysis of amyloid beta binding proteins in human plasma
Green, P. S., Kulstad, J. J., Chea, H. K., & Craft, S. (2006) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2006.05.1365 · Cited by 1 · see citing works
Therapeutic Albumin Binding to Remove Amyloid-β
Costa, M., Ortiz, A. M., & Jorquera, J. I. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-111139 · Cited by 52 · see citing works

Authors: Kuo, Y.-M., Kokjohn, T. A., Kalback, W., Luehrs, D., Galasko, D. R., Chevallier, N., Koo, E. H., Emmerling, M. R., & Roher, A. E.
Affiliations: Banner Sun Health Research Institute (US)
Midwestern University (US)
University of California San Diego (US)
Corresponding author: Roher, Alex E.
ORCID: Kuo, Yu-Min
Galasko, Douglas R.
Koo, Edward H.
Venue: Biochemical and Biophysical Research Communications
Publisher: Elsevier BV
Published: 2000-02
Volume: 268
Issue: 3
Pages: 750-756
ISSN: 0006-291X (ISSN-L)
DOI: 10.1006/bbrc.2000.2222
OpenAlex: W2046703193
Cited by: 230
References: 46
Citations by year: 2026: 7 · 2025: 9 · 2024: 10 · 2023: 11 · 2022: 10 · 2021: 15 · 2020: 7 · 2019: 14 · 2018: 8 · 2017: 16 · 2016: 13 · 2015: 7 · 2014: 12 · 2013: 7 · 2012: 8
FWCI: 2.66
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Biochemical and Biophysical Research Communications (publishedVersion)
PubMed (publishedVersion)
Funders: National Institute on Aging (P50AG005131, AG-O5131)
Topics: Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Interaction Studies and Fluorescence Analysis
Keywords: amyloid-beta, immunoassay interference, human serum albumin, alpha2-macroglobulin, erythrocytes, amyloid-beta 42, Alzheimer's disease
MeSH terms: Aged, Aged, 80 and over, alpha-Macroglobulins, Alzheimer Disease, Blood Chemical Analysis, Blood Proteins, Erythrocytes, Female, Humans, Immunoassay, Male, Middle Aged, Peptide Fragments, Protein Binding, Serum Albumin, Case-Control Studies, Amyloid beta-Peptides, In Vitro Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Amyloid-β Peptides Interact with Plasma Proteins and Erythrocytes: Implications for Their Quantitation in Plasma

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks